Related Experiment Video
Updated: Jun 2, 2026
Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
Ectonucleoside triphosphate diphosphohydrolase 6 expression in testis and testicular cancer and its implication in
Yasuhiro Tada1, Akira Yokomizo, Masaki Shiota
1Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Abstract:
The development of resistance to cisplatin during treatment of testicular cancer constitutes a major obstacle to the cure of testicular cancer. To resolve its mechanism will provide useful information for making clinical decisions. We found 4 and 15 gene expressions were, respectively, up-regulated and down-regulated in cisplatin-resistant testicular cancer NEC-8/DDP cells compared with their parental NEC-8 cells (about 2.5-fold) using cDNA microarray analysis. After screening, we selected the ENTPD6 among these 19 genes. ENTPD6 was less expressed in cancerous region compared with that in non-cancerous lesion. In addition, ENTPD6 expression in seminoma was higher than that in other testicular tumors. ENTPD6 expression was involved in cellular sensitivity to cisplatin through an interaction with E-cadherin. ENTPD6 is a promising molecular biomarker of cisplatin resistance in testicular cancer, and also a novel therapeutical target modulating cisplatin resistance in testicular cancer.
Insights
Cisplatin resistance in testicular cancer is a significant challenge. Researchers identified ENTPD6 as a key gene involved in this resistance, offering potential new therapeutic targets and biomarkers for improved treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cisplatin resistance is a major hurdle in treating testicular cancer.
- Understanding the mechanisms of resistance is crucial for clinical decision-making.
Purpose of the Study:
- To investigate the molecular mechanisms underlying cisplatin resistance in testicular cancer.
- To identify potential biomarkers and therapeutic targets for overcoming cisplatin resistance.
Main Methods:
- Utilized cDNA microarray analysis to compare gene expression in cisplatin-resistant (NEC-8/DDP) and parental (NEC-8) testicular cancer cells.
- Screened differentially expressed genes to identify key candidates.
- Analyzed ENTPD6 expression in cancerous versus non-cancerous tissues and different tumor types.
Main Results:
- Identified 19 differentially expressed genes, with ENTPD6 selected for further study.
- Found that ENTPD6 expression was lower in cancerous regions compared to non-cancerous lesions.
- Observed higher ENTPD6 expression in seminoma compared to other testicular tumors.
- Demonstrated that ENTPD6 expression influences cellular sensitivity to cisplatin via interaction with E-cadherin.
Conclusions:
- ENTPD6 is a promising molecular biomarker for cisplatin resistance in testicular cancer.
- ENTPD6 represents a novel therapeutic target for modulating cisplatin resistance.
